Press Portal

Cancer therapy: How our cells are becoming resistant to medication

New study gives hope for more effective therapies
Alternativtext

Description: Cancers can occur in any age group,
however a common clinical problem across these
diseases is the development of resistance to
therapeutics (e.g. chemotherapy or antibody treatments)
often worsening the prospects for the individual patient.
Figure: Cell Reports

Human cells are constantly changing shape. Biologists know that these morphological changes reflect changes in a cell’s function but our ability to understand the meaning behind a cell’s shape has, to date, been limited. In their new study Rune Linding from Humboldt-Universität zu Berlin (HU) and his colleagues have utilized artificial intelligence to learn, and interpret, changes in the morphology of cancer cells in order to understand how these cells are becoming resistant to cancer medication.

The researchers used an artificial intelligence (algorithm) to analyse the morphology of about 850 million cancer cells, over a period of three months, far greater a number than a biologist would be capable of analysing. This gave the machine a unique insight into very subtle changes, invisible to the human eye, in morphology that cancer cells undergo when becoming resistant to therapies.

Not only was the algorithm able to accurately predict which cancer cells were resistant to drug just by 'looking' at them but it was also able to suggest which proteins in the cells were likely driving this drug resistance.

The researchers hope that this knowledge can be used to develop better anti-cancer therapies, or therapies that can potentially reverse drug resistance in the future.

"It is becoming increasingly clear that the analysis of cell morphology using deep learning algorithms can be used to identify and classify tumours in clinical tissue scans. However, we are just scratching the surface regarding the clinical implications; moving forward we believe that morphology can supplement, and perhaps even replace, genetic analyses of tumours in the discovery of better cancer therapies," says Rune Linding, Lead Researcher of the REWIRE Project at the HU.

Publication

Link to the study 

Further information

Link to lindinglab.science

Contact

Rune Linding, PhD
Lead Researcher - REWIRE

Humboldt-Universität zu Berlin
Faculty of Life Sciences
Department of Biology

Phone: +49 1522 136 7030
rune.linding@hu-berlin.de